MARKET

ACRV

ACRV

Acrivon Therapeutics, Inc.
NASDAQ
1.150
+0.050
+4.55%
After Hours: 1.160 +0.01 +0.87% 19:17 05/16 EDT
OPEN
1.120
PREV CLOSE
1.100
HIGH
1.290
LOW
1.115
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
10.16
52 WEEK LOW
1.090
MARKET CAP
36.06M
P/E (TTM)
-0.5183
1D
5D
1M
3M
1Y
5Y
1D
Acrivon Therapeutics Cut to Hold From Buy by Jones Trading
Dow Jones · 1d ago
Jones Trading Downgrades Acrivon Therapeutics to Hold
Benzinga · 1d ago
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
TipRanks · 1d ago
Acrivon Therapeutics, Inc. (ACRV) was downgraded to a Hold Rating at JonesTrading
TipRanks · 1d ago
Acrivon Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 2d ago
Acrivon Therapeutics Price Target Cut to $9.00/Share From $10.00 by Oppenheimer
Dow Jones · 2d ago
Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10
Seeking Alpha · 2d ago
ACRIVON THERAPEUTICS INC. <ACRV.O>: OPPENHEIMER CUTS TARGET PRICE TO $9 FROM $10
Reuters · 2d ago
More
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Webull offers Acrivon Therapeutics Inc stock information, including NASDAQ: ACRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRV stock methods without spending real money on the virtual paper trading platform.